Funding agency: This study was funded by Zafgen, Inc.
Ascending dose-controlled trial of beloranib, a novel obesity treatment for safety, tolerability, and weight loss in obese women
Article first published online: 25 MAY 2013
Copyright © 2013 The Obesity Society
Volume 21, Issue 9, pages 1782–1788, September 2013
How to Cite
Hughes, T. E., Kim, D. D., Marjason, J., Proietto, J., Whitehead, J. P. and Vath, J. E. (2013), Ascending dose-controlled trial of beloranib, a novel obesity treatment for safety, tolerability, and weight loss in obese women. Obesity, 21: 1782–1788. doi: 10.1002/oby.20356
Disclosure: Dr. Hughes: employment, board membership and holding stock at Zafgen, which has filed multiple patents related to the compound and its usage. Dr. Vath: employment and holding stock at Zafgen. Dr. Kim: employment at Zafgen, financial compensation for board membership at Alkermes, DiaMedica and GI Dynamics, and consultant for Gilead, Amylin, Vivus, Lumena, Orexigen, DiaMedica, Metabolon, Alkermes and GI Dynamics, payment for lectures or serving on speakers bureaus at Amylin and Sharp Hospital, and holding stock in Amylin, Orexigen, Vivus, and Zafgen. Dr. Proietto: payment (made directly to the institution, Austin Health) for conducting the study, paid consultant on the medical advisory boards at Novo Nordisk, Janssen, Astra Zenica and Eli Lilly. Dr. Whitehead: funding (paid directly to the institution) from Zafgen to for personnel/consumables to perform assays. Dr. Marjason declares no conflict of interest.
- Issue published online: 23 SEP 2013
- Article first published online: 25 MAY 2013
- Accepted manuscript online: 20 MAR 2013 01:54AM EST
- Manuscript Accepted: 7 DEC 2012
- Manuscript Received: 17 APR 2012
- Zafgen, Inc
This article has been cited by:
- 1Weight Management in Type 2 Diabetes: Current and Emerging Approaches to Treatment, Diabetes Care, 2015, 38, 6, 1161, ,